Brian Powl
Corporate Officer/Principal presso KURA ONCOLOGY, INC.
Patrimonio netto: 460 567 $ in data 31/05/2024
Profilo
Brian T.
Powl is currently the Chief Commercial Officer at Kura Oncology, Inc. He previously worked as the Vice President-Global Commercial CAR T Lead at Celgene Corp., Senior VP-Commercial Development & Marketing at MEI Pharma, Inc., and Chief Commercial Officer at Fate Therapeutics, Inc. Powl received his undergraduate degree from the University of California San Diego and his MBA from The Wharton School of the University of Pennsylvania.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
KURA ONCOLOGY, INC.
0.02% | 02/01/2024 | 15 000 ( 0.02% ) | 309 150 $ | 31/05/2024 |
FATE THERAPEUTICS, INC.
0.04% | 05/07/2023 | 41 146 ( 0.04% ) | 151 417 $ | 31/05/2024 |
Posizioni attive di Brian Powl
| Società | Posizione | Inizio |
|---|---|---|
| KURA ONCOLOGY, INC. | Corporate Officer/Principal | 14/08/2023 |
Precedenti posizioni note di Brian Powl
| Società | Posizione | Fine |
|---|---|---|
| CELGENE | Corporate Officer/Principal | - |
| FATE THERAPEUTICS, INC. | Corporate Officer/Principal | - |
| MEI PHARMA, INC. | Vendite & Marketing | - |
Formazione di Brian Powl
| University of California San Diego | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| MEI PHARMA, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| KURA ONCOLOGY, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Borsa valori
- Insiders
- Brian Powl
